Filing summary
Issuer and period: The supplied filing is Access Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2012, filed August 14, 2012. This does not match the request metadata naming Abeona Therapeutics Inc.; verify issuer identity before relying on this summary.
Business context
Access describes itself as an emerging biopharmaceutical company focused on drug-delivery technologies. Its marketed product was MuGard for oral mucositis; ProLindac and thiarabine were in clinical development, with other programs preclinical. The company reported ongoing operating losses and dependence on financing and licensing arrangements.
Financial performance and liquidity
- Revenue: Q2 2012 revenue was $690,000, versus $150,000 in Q2 2011. For the first six months, revenue was $2.527 million, versus $300,000. Six-month licensing revenue included $706,000 of previously deferred European license fees and a $500,000 termination fee following the termination of the MuGard agreement with SpePharm. U.S. MuGard sales were $615,000 for Q2 and $1.169 million for the first half, compared with $42,000 and $55,000, respectively, in 2011.
- Loss: Net loss allocable to common stockholders was $11.039 million in Q2 2012, or $0.46 per share, versus $1.706 million, or $0.09 per share, in Q2 2011. For the first half, it was $16.371 million, or $0.68 per share, versus $4.043 million, or $0.21 per share. The 2012 losses included preferred-stock derivative remeasurement losses of $9.410 million in Q2 and $11.870 million for the first half, as well as a $2.316 million first-quarter warrant-extension expense.
- Expenses: First-half operating expenses were $4.668 million, slightly below $4.702 million a year earlier. R&D declined to $1.404 million from $1.916 million, while SG&A rose to $3.069 million from $2.620 million, primarily reflecting increased MuGard selling costs.
- Cash flow: Operating cash used was $1.857 million in the first half, compared with $2.648 million in 2011. Cash and cash equivalents fell to $588,000 at June 30, 2012, from $2.460 million at year-end. Management reported a net cash burn rate of approximately $263,000 per month.
- Liquidity and debt: Working capital deficit was $12.015 million, versus $8.877 million at December 31, 2011. Total assets were $2.437 million and total liabilities $33.510 million; stockholders’ deficit was $31.073 million. A $2.75 million secured note, secured by all company assets, was due September 13, 2012; the company stated it did not have funds to repay it. Accrued preferred dividends were $7.517 million, and accrued liquidated damages related to registration obligations were $857,000.
Material changes, outlook and risks
- MuGard U.S. sales increased substantially from a low prior-year base. China had granted MuGard marketing approval, and the company reported that manufacturing was expected to commence to meet anticipated demand.
- The European MuGard partner agreement with SpePharm was terminated by mutual agreement; commercial availability through SpePharm could continue for up to six months, and Access was seeking a replacement partner.
- Management expected available capital, MuGard receipts and expected license payments to fund the current operating level only into the third quarter of 2012. It said additional financing was required immediately and warned that inability to obtain capital or licensing agreements could threaten continued operations and going-concern status. Management also said it lacked funds to repay the secured note.
- Management reported staff reductions, reduced hours and deferred executive salaries to conserve cash. It expected continued losses while investing in research, development and clinical work and gave no assurance of achieving profitability.
- Interim MuGard post-marketing trial results presented in June 2012 reported statistically significant delays in oral mucositis onset and, in specified trial populations, reduced pain and weight loss. These were interim findings, not a reported final trial outcome.
- Disclosure controls were deemed ineffective because a previously identified material weakness remained: financial reporting depended on the CFO without adequate segregation of duties and review. Management said this had not caused a restatement and did not believe it affected the current-period statements.
Investor verification priorities
- Confirm the issuer: the filing identifies Access Pharmaceuticals, Inc., not Abeona Therapeutics Inc.
- Verify subsequent financing, debt repayment or restructuring around the September 13, 2012 note maturity, and the company’s going-concern status.
- Review the preferred-stock conversion and warrant terms underlying the substantial derivative-liability remeasurement and potential dilution.
- Assess the sustainability and cash conversion of MuGard sales, the European partner transition, and the timing and collectability of licensing receipts.
- Check subsequent clinical updates for ProLindac, thiarabine and the MuGard post-marketing study, and any remediation of the material weakness in financial controls.